Centessa Pharmaceuticals (CNTA) AI Stock Analysis

• Market Cap: $1.58B
• Dividend Yield: N/A
• Average Volume (3M): 1.17M
• Price to Earnings (P/E): ―
• Beta (1Y): 1.61
• Revenue Growth: -100.00%
• EPS Growth: -25.86%
• Country: US
• Employees: 77
• Sector: Healthcare
• Sector Strength: 73
• Industry: Biotechnology
• EPS (TTM): -1.99
• Shares Outstanding: 133,184,340
• 10 Day Avg. Volume: 1,361,130
• 30 Day Avg. Volume: 1,168,664
• PEG Ratio: N/A
• Price to Book (P/B): N/A
• Price to Sales (P/S): 303.02
• Price to Cash Flow (P/CF): -24.30
• P/FCF Ratio: 0.00
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: $32.00
• Price Target Upside: 170.50% Upside
• Rating Consensus: Strong Buy
• Number of Analyst Covering: 7

Centessa Pharmaceuticals faces significant challenges, including persistent financial losses and negative cash flow, which are major concerns. The bearish technical indicators and poor valuation metrics further contribute to a low overall stock score. The company's financial instability and the need for potential additional funding to sustain operations in a capital-intensive industry are key risks.

Positive Factors

Financial Stability

The company reported approximately $482M in cash and equivalents, which management expects to fund operations into mid-2027.

Product Efficacy

ORX750's strong initial profile is confirmed by statistically significant separation on measures of efficacy at all evaluation points.

Safety Profile

ORX750 has demonstrated a clean safety profile with no evidence of visual disturbances or hepatotoxicity.

Negative Factors

Clinical and Regulatory Risks

There are clinical, regulatory, and commercial risks associated with pipeline products and financing.

R&D Financial Impact

CNTA reported a one-time R&D charge of $31.5M related to the discontinuation of the hemophilia program, SerpinPC.

Centessa Pharmaceuticals Business Overview & Revenue Model

Company Description

Centessa Pharmaceuticals plc, a clinical-stage pharmaceutical company, discovers, develops, and delivers medicines to patients. Its registrational pipeline products include Lixivaptan, a vasopressin V2 receptor small molecule inhibitor that is in Phase III clinical development for the treatment of autosomal dominant polycystic kidney disease; and SerpinPC, an activated protein C inhibitor, which is in Phase IIa clinical development for the treatment of hemophilia A and B. The company also has emerging pipeline products under clinical proof of concept stage comprising LB101, a PD-L1xCD47 LockBody, as well as LB201, a PD-L1xCD3 LockBody, which are designed to selectively drive potent CD47 and CD3 effector function activity while avoiding systemic toxicity; ZF874, a small molecule pharmacological chaperone folding corrector of the Z variant of alpha-1-antitrypsin in Phase I clinical development for the treatment of alpha-1-antitrypsin deficiency; MGX292, a recombinant modified BMP9 replacement protein designed to overcome the deficiency in BMP9 signaling in Pulmonary Arterial Hypertension; and OX2R Agonists that are oral and intranasal selective orexin receptor 2 agonists designed to leverage structural insights and to directly target the underlying pathophysiology of orexin neuron loss in Narcolepsy Type 1. In addition, the company has exploratory pipeline products under clinical proof of concept stage containing CBS001, an anti-LIGHT antibody, which preferentially binds the inflammatory membrane form of LIGHT in inflammatory/fibrotic diseases; and CBS004, a humanized mAb specific to BDCA2, expressed exclusively on plasmacytoid dendritic cells in systemic sclerosis, systemic lupus erythematosus, and other autoimmune diseases. Centessa Pharmaceuticals plc was incorporated in 2020 and is based in Altrincham, the United Kingdom.

How the Company Makes Money

Centessa Pharmaceuticals generates revenue primarily through the research and development of novel drug candidates, which it aims to bring to market either independently or through strategic partnerships. The company invests in early-stage and clinical development of drug candidates, seeking to advance them through the pipeline to commercialization. Revenue streams are expected to include sales of approved therapies, milestone payments, and royalties from collaborations with larger pharmaceutical companies. Additionally, Centessa may engage in licensing agreements that provide upfront payments and future royalties, contingent upon the success of its drug candidates in clinical trials and eventual market approval.

Centessa Pharmaceuticals Financial Statement Overview

Summary

Centessa Pharmaceuticals faces significant financial challenges, with ongoing losses and negative cash flow. Despite a relatively strong equity position, the company's increasing debt and poor profitability metrics pose risks to its financial stability.

Income Statement

Centessa Pharmaceuticals has struggled to generate revenue consistently, with zero revenue in multiple years and a significant decline from 2023 to 2024. The company has consistently recorded negative EBIT and net income, indicating persistent operational challenges. The net profit margin remains negative, reflecting ongoing losses.

Balance Sheet

The company's balance sheet shows a relatively strong equity position with stockholders' equity exceeding liabilities, resulting in a positive equity ratio. However, the debt-to-equity ratio is concerning due to increasing total debt over the years. The company maintains a solid cash and short-term investments position, but overall financial stability is compromised by ongoing losses.

Cash Flow

Centessa Pharmaceuticals exhibits negative operating and free cash flows, highlighting liquidity challenges. Although there was a significant inflow from financing activities, the free cash flow to net income ratio is unfavorable, and cash flow from operations continues to be negative, indicating potential cash management issues.

Breakdown
Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement		Total Revenue
0.00	6.85M	0.00	0.00	0.00
	Gross Profit
0.00	6.85M	-130.92K	-33.99K	0.00
	EBIT
-201.06M	-171.28M	-212.26M	-139.31M	-10.44M
	EBITDA
-201.06M	-166.07M	-212.26M	-379.16M	-10.43M
	Net Income Common Stockholders
-235.76M	-151.09M	-216.21M	-381.85M	-11.04M
Balance Sheet		Cash, Cash Equivalents and Short-Term Investments
482.18M	256.55M	393.64M	595.08M	7.23M
	Total Assets
576.80M	360.25M	444.31M	629.63M	11.72M
	Total Debt
8.29M	84.59M	69.80M	75.70M	5.63M
	Net Debt
-374.94M	-43.44M	-323.84M	-519.38M	-1.60M
	Total Liabilities
175.25M	124.00M	108.14M	138.08M	34.14M
	Stockholders Equity
401.55M	236.24M	336.17M	491.55M	-22.42M
Cash Flow		Free Cash Flow
-142.09M	-160.51M	-201.68M	-136.33M	-10.63M
	Operating Cash Flow
-142.06M	-160.34M	-200.55M	-136.14M	-10.63M
	Investing Cash Flow
31.27M	-127.00M	-931.00K	63.25M	0.00
	Financing Cash Flow
364.75M	21.12M	457.00K	660.07M	1.36M

Centessa Pharmaceuticals Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 11.83
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Positive
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For CNTA, the sentiment is Negative. The current price of 11.83 is below the 20-day moving average (MA) of 13.32, below the 50-day MA of 15.34, and below the 200-day MA of 14.85, indicating a bearish trend. The MACD of -1.19 indicates Positive momentum. The RSI at 36.68 is Neutral, neither overbought nor oversold. The STOCH value of 58.27 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for CNTA.

Centessa Pharmaceuticals Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
AGIO	56 Neutral	$1.58B	2.44	57.29%	―	36.07%	―
ARWR	50 Neutral	$1.77B	―	-600.68%	―	-98.62%	-86.21%
KYMR	50 Neutral	$1.65B	―	-36.38%	―	-40.11%	-17.79%
Sector *	50 Neutral	$5.51B	2.95	-43.70%	2.78%	16.94%	3.59%
GLPG	49 Neutral	$1.58B	20.39	7.21%	―	―	―
BEAM	39 Underperform	$1.70B	―	-43.94%	―	-83.18%	-144.95%
CNTA	30 Underperform	$1.58B	―	-73.75%	―	-100.00%	-25.86%

Centessa Pharmaceuticals Corporate Events

Centessa Pharmaceuticals Updates on OX2R Agonist Pipeline

Centessa Pharmaceuticals announced updates on its OX2R agonist pipeline, including ORX750, ORX142, and ORX489, with significant clinical milestones anticipated in 2025. The company aims to position itself as a leader in the emerging category of OX2R agonist therapeutics, bolstered by a strong balance sheet and an estimated cash runway into mid-2027.